Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $995 from $975 and keeps a Buy rating on the shares after a “strong performance” in Q1. Key upcoming catalysts include fianlimab plus Libtayo Phase 3 data in first-line metastatic melanoma due in Q2, FDA decisions on the Eylea HD pre-filled syringe in Q2 and an FDA decision on cemdisiran in gMG due in Q4, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Earnings Strength and Pipeline Optionality Support Buy Rating as 12-Month Price Target Ticks Up to $968
- Regeneron price target lowered to $788 from $796 at Morgan Stanley
- Regeneron price target lowered to $796 from $801 at Truist
- Regeneron price target lowered to $762 from $779 at RBC Capital
- Regeneron: Buy Rating Reiterated as Analyst Sees Melanoma Trial Sell-Off Overdone; $900 Price Target Unchanged